Until recently, there were few advances over the past two decades in the options available for medical management of symptomatic endometriosis. First-line medical therapies for patients with either documented or clinically suspected endometriosis have typically included the use of continuous combination oral contraceptives, nonsteroidal antiinflammatory drugs, and oral or injectable progestins. Second-line therapy for those who do not respond to this initial approach has included danazol (which has generally been abandoned owing to androgenic side-effects), intrauterine progestins, and GnRH agonists.
沒有留言:
張貼留言